2
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Phase 2
1
Status
Recruiting
1
Active not recruiting
1
Sponsor Class
OTHER
1
INDUSTRY
1
Study Type
Interventional
2
Sponsor
Cancer Type
Gastrointestinal
2
Conditions
Colorectal Neoplasms
73
Colonic Neoplasms
14
Rectal Neoplasms
13
Neoplasm Metastasis
12
Stomach Neoplasms
8
Pancreatic Neoplasms
5
Advanced Solid Tumors
5
Neoplasms
4
Colorectal Cancer Metastatic
4
Parkinson Disease 4, Autosomal Dominant Lewy Body
3
Gallbladder Neoplasms
3
Cholangiocarcinoma
3
Carcinoma
3
Adenocarcinoma
3
Neutropenia
2
Carcinoma, Non-Small-Cell Lung
2
Carcinoma, Hepatocellular
2
Breast Neoplasms
2
Biliary Tract Neoplasms
2
Bile Duct Neoplasms
2
Advanced Solid Tumors (Excluding Breast Cancer)
2
Advanced Colorectal Cancer
2
Adenocarcinoma Of Esophagus
2
mCRC
1
Urologic Diseases
1
Urinary Bladder Neoplasms
1
Triple Negative Breast Neoplasms
1
Spinocerebellar Degenerations
1
Solid Tumor Cancer
1
Solid Tumor
1
Interventions
Fluorouracil
67
Radiotherapy
53
Cisplatin
52
Oxaliplatin
47
Leucovorin
37
Paclitaxel
36
Irinotecan
27
Docetaxel
23
Capecitabine
20
Nivolumab
17
Carboplatin
16
pembrolizumab
15
Radiation
15
Neoadjuvant Therapy
15
Surgical Procedures, Operative
12
Cetuximab
12
durvalumab
9
Drug Therapy
9
Biopsy
9
Taxes
8
Folfox protocol
8
Chemotherapy, Adjuvant
8
Trastuzumab
7
Magnetic Resonance Spectroscopy
7
Gefitinib
7
Endoscopy
7
tremelimumab
6
Specimen Handling
6
Endoscopy, Digestive System
6
Ramucirumab
5
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Adenocarcinoma Of Esophagus
×
trifluridine tipiracil drug combination
×
Clear all
NCT06356311
2026-02-27
TroFuse-015
Merck Sharp & Dohme LLC
Phase 3
Active not recruiting
450 enrolled
NCT05476796
2024-10-24
LOGICAN
UNICANCER
Phase 2
Recruiting
118 enrolled